Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merits of any Takeda bid for Shire questioned, shares slide

03/29/2018 | 03:43am EDT
FILE PHOTO: Vitamins made by Shire are displayed at a chemist's in northwest London

TOKYO (Reuters) - A potential acquisition of London-listed Shire (>> Shire) by Takeda Pharmaceutical (>> Takeda Pharmaceutical Co Ltd) was greeted with investor scepticism about its merits on Thursday, with shares in the Japanese drug maker tumbling 7 percent.

TOKYO (Reuters) - A potential acquisition of London-listed Shire by Takeda Pharmaceutical was greeted with investor scepticism about its merits on Thursday, with shares in the Japanese drug maker tumbling 7 percent.

Takeda, currently worth some $39 billion, is smaller than Shire, a rare disease specialist which saw its shares jump 16 percent to be valued at some $45 billion after the Japanese firm said it was in a "preliminary and exploratory stage" of considering a bid.

That similarity in size has raised the question of whether the damage to Takeda's finances would be worth the boost to its portfolio and pipeline.

"The impression left by the news is that the acquisition would be an overreach," said Mizuho Securities analyst Hiroshi Tanaka in a note to clients.

Any deal is expected to involve some form of equity, whether that be a share swap or a share issue, analysts also said, noting a share issue could be highly dilutive for Takeda shareholders.

Takeda said an acquisition of Shire, which also sells treatments for attention deficit disorder, could create a global biopharmaceutical leader, boost its position in the United States and in the fields of oncology, gastrointestinal diseases and neuroscience.

But some analysts also doubted whether Shire's treatments for haemophilia and other rare diseases would benefit Takeda and thought that any deal should be more targeted.

"We think neuroscience assets alone, which Shire said are under strategic review, would be a realistic target, but we find it hard to imagine Takeda acquiring all of Shire," said UBS analyst Atsushi Seki.

"We think the possibility of it making a proposal is very low, but its share price will likely be under pressure from concern over potential dilution."

Takeda's potential bid for Shire, most of whose employees are based in North America, immediately stoked expectations for another takeover battle in the deal-hungry pharma industry.

In recent months, France's Sanofi agreed to buy U.S haemophilia specialist Bioverativ for $11.6 billion and Belgium's Ablynx for 3.9 billion euros (£3.41 billion). Before that, U.S.-based Celgene bought cancer specialist Juno Therapeutics.

Japanese companies, faced with a rapidly shrinking population, are seen as particularly acquisitive. Takeda, founded in 1781 as a purveyor of traditional herbal medicine, has sought to internationalise through deals under its French CEO Christophe Weber, who took over in 2015.

(This story refiles to fix typographical error in first paragraph.)

(Reporting by Ritsuko Ando and Minami Funakoshi; Editing by Edwina Gibbs)

By Ritsuko Ando and Minami Funakoshi


© Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
CELGENE 0.10% 108.24 End-of-day quote.68.89%
SANOFI 1.38% 85.11 Real-time Quote.8.14%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.12% 3203 End-of-day quote.-14.70%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/21TAKEDA PHARMACEUTICAL : to Hold Second Quarter FY2021 Earnings Conference Calls
PU
10/20NOVAVAX : Dismisses Media Report on COVID-19 Vaccine Quality, Production Delays; Shares Do..
MT
10/20NOVAVAX : Refutes Media Report on its COVID-19 Vaccine Quality, Production Delays
MT
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
10/18Wave Life Sciences Ltd. Announces an Amendment to its Ongoing Collaboration with Takeda..
CI
10/18CALITHERA BIOSCIENCES : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipel..
MT
10/18Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from ..
CI
10/18Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
DJ
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
10/13TR1 : Notification of Major Shareholding
DJ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 398 B 29 936 M 29 936 M
Net income 2022 249 B 2 191 M 2 191 M
Net Debt 2022 3 258 B 28 699 M 28 699 M
P/E ratio 2022 20,4x
Yield 2022 5,62%
Capitalization 5 037 B 44 294 M 44 374 M
EV / Sales 2022 2,44x
EV / Sales 2023 2,29x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 203,00 JPY
Average target price 4 372,86 JPY
Spread / Average Target 36,5%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-14.70%44 294
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979